Baird Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Positive 89.5%

Neg 0% Neu 0% Pos 89.5%

Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price target from $62 to $85.